CARA News and Press, Cara Therapeutics Inc. From 03/08/21

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients STAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 (GLOBE ...

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of 23 August 2021 If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patients Regulatory News: This press release features multimedia. V...

Image source: The Motley Fool. Cara Therapeutics Inc (NASDAQ: CARA) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cara Therapeutics Inc (CARA) Q4 2020 Earnings Call Transcript

Cara Therapeutics, Inc. (CARA) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Jack Hildick-Smith - Stern IR Derek Chalmers - Chief Executive Officer Thomas Reilly - Chief Financial Officer Conference Call Participants Avatar Jones - Stifel Financial Corp. B...

Cara Therapeutics (CARA): Q4 GAAP EPS of $1.59 beats by $1.11.Revenue of $112.1M (+2391.1% Y/Y) beats by $63.47M.Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing unrestricted cash and cash equivalents and available-for-sal...

– U.S. FDA Accepts NDA Filing for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on d...

STAMFORD, Conn., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...

Today, we take an in-depth look at Cara Therapeutics, a name we have not revisited in some time. The company recently filed an NDA with the FDA and could have an eventful 2021 on the horizon. An updated investment analysis on Cara Therapeutics follows in the paragraphs below. ...

On Wednesday, Jazz Pharmaceuticals (JAZZ) said it would acquire GW Pharma (GWPH) in a $7.2B deal.Acquisition gives Jazz access to GW's cannibinoid drug for seizures, Epidiolex, as well as other cannibinoid-based therapies in the pipeline.Several other biopharmas are exploring cannibinoid trea...

Cannabis stocks could see new highs this year. Fueling momentum, Jazz Pharmaceuticals (NASDAQ:JAZZ) said it would acquire GW Pharmaceuticals (NASDAQ:GWPH) to help strengthen its neuroscience business with GWPH’s cannabis-based epilepsy treatment. That also set in motion stren...